藥品市場股票交易趨勢回顧： 2005 年第 4 季

本報告已在2011年12月21日停止出版。

簡介

目錄

Abstract

In This Issue.

Aside from biotechnology's continued hot streak on Wall Street, the fourth quarter was a quiet one for the life sciences industry, which raised only $6.4 billion in financings, the lowest quarterly total of 2005. Only four initial public offerings (IPOs) were made in the United States, and both alliance and ownership activity dropped dramatically. Secondary public offerings (SPOs) were the only financial vehicle that increased over the third quarter's totals, and biotech stocks turned in a strong fourth quarter, outperforming the life sciences industry and the U.S. economy as a whole. In this report, we review the fourth quarter's IPOs, SPOs, debt financings, private placement and venture capital activity, ownership changes, and company alliances. We also examine the most active pharmaceutical and biotech companies of the quarter. In addition, we take an in-depth look at the year-end bidding war for Guidant that drew the attention of the life sciences industry--as well as the business world in general--by highlighting the current and likely continued profitability of drug-eluting stents in the cardiovascular industry.

Table of Contents

Overview Major Corporate Events in Cardiology?A Year-End Bidding War over Drug-Eluting Stents

• A Brief Look at Guidant
• Why Guidant Was Attractive to Johnson & Johnson
• Why Guidant Was Attractive to Boston Scientific
• Backed by Abbott, Boston Scientific Prevails
• Warning Letter from the FDA and Device Safety Issues
• Patent Struggles Continue
• Future Acquisition Candidates for Johnson & Johnson

Financings

• Initial Public Offerings
• Secondary Public Offerings
• Debt Financings
• Private Placements and Venture Capital

Ownership Changes

• Novartis/Chiron
• Allergan/Inamed
• Amgen/Abgenix
• St. Jude Medical/Advanced Neuromodulation Systems

Alliances

• AstraZeneca/AtheroGenics
• Pfizer/Incyte
• AstraZeneca/Protherics
• Roche/BioCryst Pharmaceuticals
• Novartis/Astex Therapeutics

Most Active Pharmaceutical Companies

Most Active Biotechnology Companies

相關商品

製藥企業相關市場調查報告書

生物標記相關合作契約
Biomarker Partnering Terms and Agreements
價格 : US $ 2695
出版日期 : 2012年02月

最佳實務：轉譯研究-朝向產業轉換前進
Best Practices: Translational Research - Positive Steps on the Path to Industry Transformation
價格 : US $ 4500
出版日期 : 2011年12月

製藥產業的合作，授權，投資，收購與合併交易趨勢:2011年12月
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - December 2011
價格 : US $ 1000
出版日期 : 2011年12月

Decision Resources, Inc.發行的製藥相關市場調查報告書

傳染病疫苗開發平台:競爭檢討

Special Report: The Infectious Disease Vaccine Pipeline--A Competitive Review

價格 : US $ 9200

出版日期 : 2011年06月

感染疾病疫苗:未滿足需求和對醫藥品產業來說的機會

Special Report: Infectious Disease Vaccines--Unmet Needs and Opportunities for Pharma

價格 : US $ 9200

出版日期 : 2011年06月

自閉症譜系障礙:高未滿足需求創造出很大的市場機會

Special Report: Autism Spectrum Disorders--High Unmet Needs Create Significant Market Opportunities

價格 : US $ 9200

出版日期 : 2011年06月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!